When I last wrote about the oncology focused company, AstraZeneca (NASDAQ: AZN ) in November, a Buy rating appeared contrarian. Following a fraud investigation in China, its price saw a sharp fall. And with no way of knowing when the matter would be resolved, itManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green e ...